Back to results
US 2024/0254245 A1Published application
Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
OwnerHua YING, Langyong MAO +2inventors
InventorsHua YING, Langyong MAO, Xiaoling GU, Weikang TAO
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to an antigen-binding molecule specifically binding to RANKL and NGF, and a medical use thereof. Specifically, provided are a novel anti-RANKL antibody, a bispecific antibody targeting RANKL and NGF, a preparation method for the antibody, and a use thereof in treatment or prevention of diseases.
Claims27
An antigen-binding molecule, comprising:
- at least one first antigen-binding domain that specifically binds to RANKL, and
- at least one second antigen-binding domain that specifically binds to NGF;
- the first antigen-binding domain that specifically binds to RANKL comprises a heavy chain variable region and a light chain variable region, wherein:
- i) the heavy chain variable region comprises:
- a HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 7;
- a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 8;
- and a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 14;
- and
- the light chain variable region comprises:
- a LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 6;
- or
- ii) the heavy chain variable region comprises:
- a HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 7;
- a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 8;
- and a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 15;
- and
- the light chain variable region comprises:
- a LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 6;
- or
- iii) the heavy chain variable region comprises:
- a HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 13;
- a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 8;
- and a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 3;
- and
- the light chain variable region comprises:
- a LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 6.
47 more elements
An anti-RANKL antibody, comprising a heavy chain variable region and a light chain variable region, wherein:
- i) the heavy chain variable region comprises:
- a HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 7;
- a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 8;
- and a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 14;
- and
- the light chain variable region comprises:
- a LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 6;
- or
- ii) the heavy chain variable region comprises:
- a HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 7;
- a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 8;
- and a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 15;
- and
- the light chain variable region comprises:
- a LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 6;
- or
- iii) the heavy chain variable region comprises:
- a HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 13;
- a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 8;
- and a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 3;
- and
- the light chain variable region comprises:
- a LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 6.
44 more elements
(canceled)
(canceled)
A method for treating pain or inhibiting bone loss, wherein the method comprises administering to an individual in need thereof an effective amount of an NGF antagonist and a RANKL antagonist;
- the NGF antagonist and the RANKL antagonist are administered simultaneously or sequentially;
- preferably, the NGF antagonist is an anti-NGF antibody and/or the RANKL antagonist is an anti-RANKL antibody.
Dependencies are inferred from the claim text.